LA CHIMIOTHERAPIE DE L’ADENOCARCINOME PROSTATIQUE : ETAT DE L’ART EN 2019

Ismail ESSADI, Issam LALYA, Mohamed KAAKOUA, Abdelhamid EL OMRANI, Mouna KHOUCHANI, Rhizlane BELBARAKA

Abstract


Le cancer de la prostate est une maladie hétérogène, avec différents aspects clinico-biologiques et évolutifs. Le plus souvent il s’agit d’une maladie à évolution indolente. La chimiothérapie a longtemps constitué une thérapie de dernier recours dans le traitement des cancers prostatiques. Déployer une chimiothérapie dans ce contexte impliquait certainement l’échec de toutes les possibilités de manipulation hormonale. C’est ainsi que la chimiothérapie antinéoplasique fut proposée d’abord en situation métastatique, en phase de résistance à la castration. De nombreuses molécules ont permis de confirmer l’efficacité de la chimiothérapie dans cette indication. Plusieurs études phases III ont permis de placer la chimiothérapie comme une option sérieuse dans des situations moins avancées, avec des résultats très encourageants en termes de survie et de qualité de vie. La chimiothérapie est considérée actuellement comme une arme thérapeutique qu’il faudrait intégrer dans la stratégie de prise en charge, après discussion en réunion de concertation pluridisciplinaire (RCP). A travers cette mise au point nous essayerons de dresser l’état de l’art de l’usage de la chimiothérapie antinéoplasique dans les adénocarcinomes prostatiques en 2018, en situations métastatique (de novo ou en phase de résistance à la castration), localisée ou localement avancée.


Keywords


Adénocarcinome - Prostate - Chimiothérapie

Full Text:

PDF

References


(1) Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.

(2) Registre des cancers de la région du grand Casablanca pour la période 2008-2012 (édition 2016)

(3) Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9–12.

(4) Essadi I, Lalya I , Elharrech Y , Ghoundale O, Touiti D. Metastatic Castration Resistant Prostate Cancer : For when a “Piecemeal” Therapeutic Strategy ? BAOJ Med Nursing 2015 1: 2 1: 009

(5) Jacques M, Dimitri D, Eugeniu B, Floriant S,Philippe B, Oudard S. Chimiothérapie du cancer de la prostate. Presse Med. 2008; 37: 814–820

(6) Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. European Urology 65(2): 289–299 2014

(7) Mohler JL . Castration-recurrent prostate cancer is not androgen- independent. Adv Exp Med Biol 617:223–234 ; 2008

(8) Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14(6): 1756– 1764 ; 1996.

(9) Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502–1512 ; 2004

(10) Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, et al. Docetaxel and estra- mustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513–1520 ; 2004.

(11) Oudard S, Banu E, Banu A, Scotte F, Levy E, Medioni J et al. Docetaxel versus mitoxantrone as first-line chemotherapy for hormone- refractory prostate cancer (HRPC) patients. A meta-analysis of 3-year overall survival results. J Clin Oncol. 2005 ASCO Annual Meeting Proceeding 2005;23(16S): Abstract 4634.

(12) Ohlmann C, Engelmann U, Heidenreich A. Second-line chemotherapy with docetaxel for prostate-specific antigen (PSA) relapse in men with hormone-refractory prostate cancer (HRPCA) previously treated with docetaxel- based chemotherapy. In: Prostate Cancer Symposium;2006;2006. Abstract No:248.

(13) Antonarakis ES, Eisenberger MA (2013) Phase III trials with docetaxelbased combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol 31(14): 1709-1712

(14) Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, et al. (2009) Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15(2): 723–730.

(15) de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J, et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open- label trial. Lancet 376(9747): 1147–1154.

(16) Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol. 2017 Oct 1;35(28):3189-3197. doi: 10.1200/JCO.2016.72.1068.

(17) Abratt RP, Brune D, Dimopoulos MA, Kliment J, Breza J, Selvaggi FP et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone refractory prostate cancer. Ann Oncol 2004;15(11):1613-21.

(18) Zampino MG, Verri E, Locatelli M, Curigliano G, Ascione G, Sbanotto A et al. Vinorelbine based chemotherapy in hormone-refractory prostate cancer. Anticancer Res 2006;26(3B): 2375-80.

(19) Mark C. Markowski , Michael A. Carducci Early use of chemotherapy in metastatic prostate cancer Cancer Treatment Reviews, Volume 55, April 2017, Pages 218-224

(20) Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149–58.

(21) Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New Engl J Med 2015;373:737–46.

(22) Gravis G, Boher JM, Joly F, et al. Androgen Deprivation Therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol 2015.

(23) James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2015.

(24) Ahlgren GM, Flodgren P, Tammela TL, et al. Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer: results from the prospective randomised, open-label phase 3 Scandinavian Prostate Cancer Group 12 trial. Eur Urol. In press. https:// doi.org/10.1016/j.eururo.2018.01.012.

(25) Lin D, Garzotto M, Aronson W, et al. VA CSP#553 chemotherapy after prostatectomy (CAP) for high risk prostate carcinoma: a phase III randomized study. J Urol 2016;195(4 Suppl):e1071.

(26) Elaine T. Lam, L. Michael Glodé. Hematol Oncol Clin N Am 27 (2013) 1189–1204 http://dx.doi.org/10.1016/j.hoc.2013.08.004




DOI: http://dx.doi.org/10.15342%2Fijms.v6ir.292

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.